Results 171 to 180 of about 162,747 (308)

The Enhanced Whey Protein Oral Bioavailability and Muscle Anabolism Ability by a Simple and Effective Piperine-Whey Protein Synergistic Codelivery System. [PDF]

Adv Sci (Weinh)
Yue Q, Wu K, Wei B, Song G, Sun C, Li X, Liu X, Ma Z, Lv M, Landman J, Li Y.   +10 more
europepmc   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Comparison of Solid Self-Nanoemulsifying Systems and Surface-Coated Microspheres: Improving Oral Bioavailability of Niclosamide

International Journal of Nanomedicine
Kyungho Baek,1 Mi Ran Woo,2 Fakhar ud Din,3 Yong Seok Choi,4 Myung Joo Kang,4 Jong Oh Kim,5 Han-Gon Choi,2 Sung Giu Jin1 1Department of Pharmaceutical Engineering, Dankook University, Cheonan, South Korea; 2College of Pharmacy, Hanyang University, Ansan,
Baek K, Woo MR, ud Din F, Choi YS, Kang MJ, Kim JO, Choi HG, Jin SG   +7 more
doaj  

Impact of Different Surfactants on Oral Bioavailability of Paclitaxel/HPMC-AS Amorphous Solid Dispersion. [PDF]

Pharmaceutics
Zhang C, Mao S, Yuan J, Ma X, Xing A, Liu X, Chen Y.   +6 more
europepmc   +1 more source

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Clinical Pharmacology &Therapeutics, EarlyView.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, Girish S. Gudi, Adam Drake, Maria Pihlgren, Piet H. van der Graaf, Sunitha GN, Andrew Garton, Mario Perro, Cyril Konto, Lida Pacaud   +11 more
wiley   +1 more source

Combined Experimental and Computational Approaches for Ternary Solid Dispersions to Enhance the Oral Bioavailability of Penfluridol. [PDF]

Pharmaceutics
Mamani M, Kim GL, Kil SM, Han HK.
europepmc   +1 more source

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug–Drug Interactions for Orforglipron, a Small Molecule Glucagon‐Like Peptide‐1 Receptor Agonist

Clinical Pharmacology &Therapeutics, EarlyView.
Orforglipron is an orally administered, small‐molecule glucagon‐like peptide‐1 receptor agonist in clinical development for the treatment of type 2 diabetes and obesity. Orforglipron is a substrate of CYP3A4, organic anion transporting polypeptides (OATPs) 1B/1B3, and P‐glycoprotein (P‐gp); however, precipitants commonly used to define these mechanisms
Bridget L. Morse, David E. Coutant, Xiaosu Ma, Sohini Raha, Keerthan Aithal, Clare Nicoll, Luc R. A. Rougée, Shobha Bhattachar   +7 more
wiley   +1 more source

Surfactant-Particle Engineering Hybrids: Emerging Strategies for Enhancing Solubility and Oral Bioavailability of Poorly Water-Soluble Drugs. [PDF]

Pharmaceutics
Kim KS, Cho HJ, Din FU, Cho JH, Choi HG.
europepmc   +1 more source

From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI

Clinical Pharmacology &Therapeutics, EarlyView.
Drug development productivity has not improved despite five decades of computational advancement, with the probability that a compound entering Phase I achieving regulatory approval remaining near 10%. Each automation wave increased throughput while leaving the interpretive bottleneck intact; scientists continued to formulate questions, evaluate ...
Michael McCoy, Matthew McCoy
wiley   +1 more source

Oral Bioavailability of a Noncoding RNA Drug, TY1, That Acts on Macrophages. [PDF]

J Extracell Biol
Yamaguchi S, Miyamoto K, Jones XM, Ciullo A, Tsi K, Anderson J, Komuro H, Soussi S, Morris A, Kitka D, Liu DZ, Nguyen A, Marbán E, Ibrahim AGE.   +13 more
europepmc   +1 more source